Halberd Corporation filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Treating and Curing Covid-19 Infection Utilizing a Laser.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “We continue to protect our technology in many countries across the globe through the PCT process. Halberd’s patented extracorporeal treatment process opens the door to treatment of Covid-19 and other diseases through exposing the target antigens to laser energy. This laser ablation methodology is being explored currently with both European and USA technology sources.
Halberd Corporation is already developing breakthrough medical technology via its planned near-term experimentation utilizing radio frequency waves at Youngstown State University to eradicate disease pathogens. The possible utilization of lasers at Youngstown State University is yet another example of Halberd’s commitment to lead the medical industry in developing new and exciting technology to eradicate all disease types. Our team has commenced planning for experimentation using a laser in a series of experimentations. We will soon set the commencement date for the laser experimentation.”
Halberd U.S. provisional patent application “Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus” was initially filed with the U.S. Patent and Trademark Office on April 21, 2020. Halberd holds exclusive worldwide license to this technology.